Silence Therapeutics Plc Receivables

Silence Therapeutics Plc's receivables stands at $9.3M as of June 2026. That compares with $20M in the prior-year period — down 53.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Silence Therapeutics Plc reported $9.3M in receivables versus $20M a year earlier — a 53.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $20M in the prior-year period — down 53.6% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Silence Therapeutics Plc's receivables evolved across reporting periods, while the comparison chart places SLN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Silence Therapeutics Plc's reading of $9.3M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.